Troglitazone in Treating Patients With Liposarcoma
Completed
National Cancer Institute (NCI)
Phase 2
1997-06-01
Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm,
open-label study with a two-stage design to evaluate troglitazone in patients with
liposarcoma stratified by histologic subtype.
Troglitazone in Treating Patients With Liposarcoma
Completed
Dana-Farber Cancer Institute
Phase 2
1997-06-01
Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm,
open-label study with a two-stage design to evaluate troglitazone in patients with
liposarcoma stratified by histologic subtype.
TART - Troglitazone Atherosclerosis Regression Trial
Completed
Parke-Davis
Phase 2/Phase 3
1997-01-01
The purpose of this study is to determine if troglitazone reduces the progression of early
preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
Completed
Takeda Pharmaceuticals North America, Inc.
Phase 1
2003-10-01
The purpose of this study is to determine whether an already FDA approved drug is safe and
tolerable in Relapsing Remitting Multiple Sclerosis patients.
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
Completed
University of Illinois at Chicago
Phase 1
2003-10-01
The purpose of this study is to determine whether an already FDA approved drug is safe and
tolerable in Relapsing Remitting Multiple Sclerosis patients.
Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients
Completed
Baskent University
Phase 4
2004-03-01
The purpose of this study was to determine the effects of rosiglitazone in normotensive type
2 diabetic patients with regard to its blood-pressure-reducing effects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
